80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]方瀟,戴天增,池哲子,等.良性前列腺增生和男性群體膀胱癌的因果效應(yīng):雙樣本孟德爾隨機(jī)化研究[J].福建醫(yī)藥雜志,2024,46(06):1-5.[doi:10.20148/j.fmj.2024.06.001]
　FANG Xiao,DAI Tianzeng,CHI Zhezi,et al.Causal effects of benign prostatic hyperplasia and bladder cancer in male population: a two-sample Mendelian randomization study[J].FUJIAN MEDICAL JOURNAL,2024,46(06):1-5.[doi:10.20148/j.fmj.2024.06.001]
點(diǎn)擊復(fù)制

良性前列腺增生和男性群體膀胱癌的因果效應(yīng):雙樣本孟德爾隨機(jī)化研究()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
46
期數(shù):
2024年06期
頁(yè)碼:
1-5
欄目:
專論
出版日期:
2024-11-15

文章信息/Info

Title:
Causal effects of benign prostatic hyperplasia and bladder cancer in male population: a two-sample Mendelian randomization study
文章編號(hào):
1002-2600(2024)06-0001-05
作者:
方瀟1; 戴天增1; 池哲子2; 朱蘭卉2; 高帥1; 葛茹茹1; 周智華1
1 福建醫(yī)科大學(xué)孟超肝膽醫(yī)院泌尿外科,福州 350001; 2 福州大學(xué)生命科學(xué)與工程學(xué)院,福州 350116
Author(s):
FANG Xiao1;  DAI Tianzeng1;  CHI Zhezi2;  ZHU Lanhui2;  GAO Shuai1;  GE Ruru1;  ZHOU Zhihua1
1 Department of Urology, MengChao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian 350001, China; 2 College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian 350116, China
關(guān)鍵詞:
膀胱癌;  良性前列腺增生;  單核苷酸多態(tài)性;  孟德爾隨機(jī)化
Keywords:
bladder cancer;  benign prostatic hyperplasia;  single nucleotide polymorphism;  Mendelian randomization
分類號(hào):
R737.14
DOI:
10.20148/j.fmj.2024.06.001
文獻(xiàn)標(biāo)志碼:
A
摘要:
目的 利用兩樣本孟德爾隨機(jī)化(MR)法探究良性前列腺增生(BPH)與男性群體膀胱癌(BCa)患病風(fēng)險(xiǎn)的因果效應(yīng)。方法 分別獲取來(lái)自FinnGen R9數(shù)據(jù)庫(kù)的BPH暴露數(shù)據(jù)(n=172 961)以及UK Biobank的BCa結(jié)果數(shù)據(jù)(n=167 020)的全基因組關(guān)聯(lián)研究數(shù)據(jù),經(jīng)篩選使用其中顯著的單核苷酸多態(tài)性位點(diǎn)作為工具變量,利用MR-PRESSO檢驗(yàn)、MR Egger法和逆方差加權(quán)(IVW)法行異質(zhì)性檢驗(yàn),去除離群值。使用MR Egger法、加權(quán)中值估計(jì)法、IVW法行MR分析,判斷兩者的因果聯(lián)系。使用MR Egger回歸檢驗(yàn)、留一法檢測(cè)結(jié)果的敏感性與多效性,確保分析結(jié)果可靠。結(jié)果 在MR分析中,MR Egger法[OR=0.999 9, 95%CI=(0.995 5,1.003 6), P=0.832]、加權(quán)中值估計(jì)法[OR=0.999 9, 95%CI=(0.998 3,1.001 5), P=0.941]、IVW法[OR=1.000 1, 95%CI=(0.999 0,1.001 2), P=0.898]均未發(fā)現(xiàn)男性人群中BPH與BCa的風(fēng)險(xiǎn)之間存在因果關(guān)系。未發(fā)現(xiàn)顯著的異質(zhì)性或多效性,敏感性分析也沒(méi)有發(fā)現(xiàn)與該假設(shè)相悖的結(jié)果。結(jié)論 孟德爾隨機(jī)化研究不支持良性前列腺增生與男性群體膀胱癌患病存在因果效應(yīng)。
Abstract:
Objective To explore the causal effect of benign prostatic hyperplasia(BPH)on the risk of bladder cancer(BCa)in the male population using the two-sample Mendelian randomization(MR). Methods Genome-wide association study data for BPH exposure data(n=172 961)from the FinnGen R9 database and BCa outcome data(n=167 020)from the UK Biobank were obtained. Significant single nucleotide polymorphism loci were selected as instrumental variables after screening. Heterogeneity tests were conducted using the MR-PRESSO test, MR Egger method, and the inverse variance-weighted(IVW)method to remove outliers. MR analyses were performed using the MR Egger method, weighted median estimate, and IVW method to assess the causal relationship. The sensitivity and pleiotropy of the results were tested using MR Egger regression test and leave-one-out method to ensure reliability of the analysis. Results In this MR analysis, no causal relationship was found between BPH and the risk of BCa in the male population using the MR Egger method, weighted median estimate, and IVW me-thod. No significant heterogeneity or pleiotropy was detected, and sensitivity analysis did not reveal any results contrary to the hypothesis.Conclusion Mendelian randomization study does not support a causal effect of benign prostatic hyperplasia on the incidence of bladder cancer in the male population.

參考文獻(xiàn)/References:

[1] BABJUK M, BURGER M, CAPOUN O, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer(Ta, T1, and carcinoma in situ)[J]. European Urology, 2022, 81(1): 75-94.
[2] SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2021[J]. CA: A Cancer Journal for Clinicians, 2021, 71(1): 7-33.
[3] RICHTERS A, ABEN K K H, KIEMENEY L A L M. The global burden of urinary bladder cancer: an update[J]. World Journal of Urology, 2019, 38(8): 1895-1904.
[4] LEE Y J, LEE J W, PARK J, et al. Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea[J]. Investigative and Clinical Urology, 2016, 57(6): 424-430.
[5] DAI X, FANG X M, MA Y, et al. Benign prostatic hyperplasia and the risk of prostate cancer and bladder cancer: a meta-analysis of observational studies[J]. Medicine, 2016, 95(18): e3493.
[6] HUNG S C, LAI S W, TSAI P Y, et al. Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk[J]. Br J Cancer, 2013, 108(9): 1778-1783.
[7] FANG C W, LIAO C H, WU S C, et al. Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study[J]. World J Urol, 2018, 36(6): 931-938.
[8] DU W, WANG T, ZHANG W, et al. Genetically supported causality between benign prostate hyperplasia and urinary bladder neoplasms: a mendelian randomization study[J]. Frontiers in Genetics, 2022, 13: e1016696
[9] GREENWALD P, KIRMSS V, POLAN A K, et al. Cancer of the prostate among men with benign prostatic hyperplasia[J]. Journal of the National Cancer Institute, 1974, 53(2): 335-340.
[10] KANG D, CHOKKALINGAM A P, GRIDLEY G, et al. Benign prostatic hyperplasia and subsequent risk of bladder cancer[J]. British Journal of Cancer, 2007, 96(9): 1475-1479.
[11] FU Y, LI J, ZHU Y, et al. Causal effects of gut microbiome on autoimmune liver disease: a two-sample Mendelian randomiza-tion study[J]. BMC Med Genomics, 2023, 16(1): 232.
[12] KURKI MI, KARJALAINEN J, PALTA P, et al. FinnGen provides genetic insights from a well-phenotyped isolated population[J]. Nature, 2023, 613(7944): 508-518.
[13] SUDLOW C, GALLACHER J, ALLEN N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age[J]. PLoS Medicine, 2015, 12(3): e1001779.
[14] BURGESS S, THOMPSON S G. Avoiding bias from weak instruments in Mendelian randomization studies[J]. International Journal of Epidemiology, 2011, 40(3): 755-764.
[15] SEKULA P, DEL GRECO M, PATTARO C, et al. Mendelian randomization as an approach to assess causality using observational data[J]. Journal of the American Society of Nephrology, 2016, 27(11): 3253-3265.
[16] YUH B, WILSON T, BOCHNER B, et al. Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy[J]. European Urology, 2015, 67(3): 402-422.
[17] LIN Y H, HOU C, JUANG H, et al. Association between bladder outlet obstruction and bladder cancer in patients with aging male[J]. J Clin Med, 2019, 8(10): 1550.
[18] GRATZKE C, BACHMANN A, DESCAZEAUD A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction[J]. European Urology, 2015, 67(6): 1099-1109.

備注/Memo

備注/Memo:
基金項(xiàng)目:福建省自然科學(xué)基金面上項(xiàng)目(2020J011172)
通信作者:周智華,Email: [email protected]
更新日期/Last Update: 2024-11-15